Requires health insurance coverage for early-stage kidney disease screening without cost sharing.
A4915 requires a broad range of New Jersey health coverage arrangements to cover medically necessary early-stage kidney disease screening without any deductible, copayment, coinsurance, or other cost sharing. The bill applies to hospital service corporations, medical service corporations, health service corporations, individual and group health insurance policies, individual and small employer health benefits plans, enrollee agreements issued by HMOs, and the State Health Benefits Program and School Employees’ Health Benefits Program. It directs coverage for screening tests used to detect early kidney disease, specifically an estimated glomerular filtration rate (eGFR) blood test or a urine albumin-creatinine ratio (uACR) urine test, when ordered by a physician.
The bill also creates a presumption that the screening is medically necessary when the physician determines the patient meets clinical guidelines established by the National Kidney Foundation, its successor, or a comparable organization. It states that the benefit must be provided to the same extent as coverage for other medical conditions and applies to policies and contracts issued, delivered, renewed, or purchased on or after the effective date, which is the first day of the fourth month after enactment. The bill includes special language for high-deductible health plans, catastrophic plans, and federal tax-advantaged accounts so that the state mandate applies only to the extent allowed under federal law.
In practical terms, the bill would amend New Jersey insurance and health benefits law across multiple statutory chapters to add kidney disease screening as a mandated covered service. It would affect commercial insurers, HMOs, and public employee health plans by requiring them to pay for the specified screening tests when medically necessary, while limiting patient out-of-pocket costs to zero for those services. The mandate is framed as a preventive and early-detection measure intended to identify chronic kidney disease earlier in its progression.
The general sentiment reflected in the bill text is strongly supportive of expanded access to screening and prevention. The statement emphasizes that chronic kidney disease incidence is rising in New Jersey and that earlier detection through eGFR and uACR testing can help identify disease before it worsens. No committee transcripts or votes were provided, so there is no recorded legislative debate or formal vote history to indicate opposition or support beyond the bill’s sponsor-driven rationale.
The main points of potential contention are likely to be the insurance mandate itself, the resulting premium impact on carriers and purchasers, and the breadth of the coverage requirement across both private and public plans. Another possible issue is the bill’s reliance on physician judgment and external clinical guidelines to trigger the presumption of medical necessity. The text also contains several drafting inconsistencies and apparent errors in references to the National Kidney Foundation and related language, which could draw technical scrutiny during committee review.
The bill would add a new mandated health benefit for early-stage kidney disease screening to multiple New Jersey insurance and health benefits statutes, including provisions governing hospital service corporations, medical service corporations, health service corporations, individual and group health policies, individual and small employer health benefits plans, HMO enrollee agreements, and the State Health Benefits and School Employees’ Health Benefits Programs. Covered plans would have to pay for physician-determined medically necessary screening using eGFR or uACR tests, and could not impose deductibles, copayments, coinsurance, or other cost sharing for those services, subject to federal law limits for high-deductible and catastrophic plans.
The bill’s overall tone is favorable toward expanding preventive care and reducing barriers to early diagnosis. Its sponsor statement presents the measure as a response to rising chronic kidney disease rates and emphasizes the value of screening before the disease progresses. Because no committee testimony or vote record was provided, there is no documented public opposition or bipartisan debate in the available materials, but the proposal appears to be framed as a health-access measure rather than a controversial policy change.
Likely points of contention include the cost to insurers and public health plans of adding a new mandated benefit, especially because the bill applies broadly across commercial and public coverage markets. Insurers and employer plan sponsors may also object to the zero-cost-sharing requirement and the potential administrative burden of determining medical necessity under external clinical guidelines. In addition, the bill’s drafting contains several apparent textual errors and inconsistent references to the National Kidney Foundation and related terms, which could raise technical concerns even among supporters of the policy goal.